By Ajay Karandikar, Founder & CEO, Omnitheia | 8 minute read

There is a conversation happening across life sciences right now. It goes roughly like this: “We tried AI. The outputs looked convincing, but we couldn’t verify them. We presented insights to leadership and were challenged on accuracy and sources. We couldn’t find it.”

That conversation is happening everywhere: in boardrooms and licensing reviews, in Medical Affairs and Regulatory strategy sessions, in the offices of portfolio leads and market access teams working under genuine deadline pressure. It is not a fringe concern. It is the defining limitation of AI as it currently exists in our industry.

At Omnitheia, this is exactly where we started. Not with the technology, but with the problem. The life sciences sector has no shortage of intelligence tools. What it lacks is insight it can trust. And trust, in this context, is a clinical and commercial requirement. A flawed insight at a licensing decision point, a hallucinated data point in a regulatory submission package, an unverifiable claim in a due diligence report – these are failures with measurable consequences, in an industry where developing a single drug costs an average of $2.3 billion and nine out of ten assets in clinical development never reach patients.

The structural problems this represents were already deeply understood by the life sciences practitioners who founded Omnitheia. The technology platform is the engineered answer to that understanding: built to solve problems that had been lived and documented, not discovered in the process of building a product. Delivering that answer required something the industry rarely finds in a single organisation: people who could architect technology capable of meeting the life sciences standard of rigor from first principles.

This article introduces two of those people.

Why the Technology Gap Has Been So Hard to Close

Because the challenge is not simply that AI makes mistakes. All systems make mistakes. The problem is that most AI tools deployed in life sciences today were not designed for life sciences.

Generic AI platforms retrieve information by casting a wide net across the open web, with no audit trail, no source hierarchy, and no mechanism for distinguishing a peer-reviewed regulatory submission from a speculative news comment. Because these systems re-query live sources at the moment of each request, outputs are only as stable as the web itself: pages are updated, paywalled, removed, or quietly revised, and the AI has no record of what it retrieved previously or why. The result is outputs that look authoritative but cannot be verified. In most industries, this is a nuisance. In life sciences, where decisions are made on the basis of clinical evidence and regulatory precedent, it is a structural risk.

A secondary problem is integration. Most life science teams carry the burden of four, five, or six intelligence subscriptions, each with its own methodology, coverage scope, and export format. Synthesizing these manually takes skilled analysts hours that could be spent on higher-value interpretation. The intelligence exists. The process of converting it into a coherent, validated picture does not.

These are the problems our platform was built to solve. Solving them required people who could think rigorously about both the data architecture and the domain application simultaneously.

Sterling Stites: Building Systems That Enterprise Decisions Depend On

Sterling Stites brings to Omnitheia a background shaped by some of the most demanding information infrastructure environments in the world.

His career spans senior development leadership roles at IBM and Dow Jones, organizations where the integrity, performance, and reliability of information systems are not aspirational standards but operational requirements. Following that, Sterling was co-founder and CEO of InfoDesk, a life science intelligence and data management platform, which he scaled over 23 years before a successful private equity exit. It is a trajectory that spans the full arc from enterprise software engineering discipline to life science domain application, with the responsibility of building and leading a company in between.

What Sterling brings to Omnitheia is more than technical seniority. It is a specific kind of judgment: an understanding of what it takes for an information platform to function reliably under the conditions that enterprise clients actually work in. Conditions where regulatory scrutiny, organization-wide deployment, and the weight of the decisions involved leave no room for outputs that cannot be verified.

Sterling’s focus at Omnitheia is on large scale life science data collection and that the platform’s infrastructure meets the institutional standards life science organizations require for consequential decisions.

Sterling describes the foundations the platform is built on:

“When building technology for life sciences, we focus on three core foundations: secure architecture, data collection, and effective workflows.

We begin with the architecture to ensure top-tier reliability and institutional-grade security. The quality of our data comes from working with a controlled, verified ‘repository of truth’ that governs every result. We then use this foundation to build and continuously improve the automated workflows our customers need.”

Mahesh Yadav: Designing AI That Accounts for What It Does Not Know

Mahesh Yadav is the Product Architect who leads development at Omnitheia, with a specific focus on the agentic AI capabilities and the automated verification systems that make the platform’s outputs trustworthy rather than merely plausible.

With 17 years of experience in scalable product architecture and enterprise AI, Mahesh brings to this problem a particular disposition: a preoccupation not just with what AI can produce, but with how it accounts for uncertainty.

The Evidence Builder that Mahesh has designed is not a feature bolted onto an existing AI workflow. It is the design philosophy expressed as a product mechanism, where the system validates the evidence to ensure the outputs are clinical-grade.

Every source is subjected to what we call a dual audit: an evaluation of a document’s inherent credibility, cross-referenced against the broader body of published evidence. Every claim carries a Confidence Score. Outliers are flagged. The logic is traceable. This is the mechanism that means you are never asked to stand behind outputs you cannot fully interrogate.

Mahesh frames the design intent directly:

“In life sciences, the question is not whether an AI output looks correct. It is whether the output can withstand scrutiny from a regulator, a licensing committee, or a clinical reviewer.

My focus has been on moving away from black-box models toward an agentic architecture that understands its own boundaries. It’s not just about the Evidence Builder; it’s about building a system that treats ‘I don’t know’ or ‘this source is unverified’ as a high-value output.

We aren’t just building a search tool; we are architecting a platform that mimics the rigor of a human analyst, ensuring that every automated insight is anchored to a stable, controlled repository of truth.”

The Architecture of Trust

What the platform required was a specific combination: infrastructure capable of meeting institutional standards for reliability, security, and scale, paired with a product purpose-built for life science data structures and validation logic.

Between the concept and the product is an enormous amount of engineering judgment, and that judgment has to be grounded in both technical experience and industry understanding. Sterling and Mahesh have built intelligence platforms together for the world’s largest pharmaceutical companies – Omnitheia is not their first time integrating these disciplines under real conditions.

Omnitheia’s approach to data is not passive. The platform curates and ingests original source documents directly. The AI does not choose its own sources from the open web. It works from a controlled, daily-updated repository of over 100,000 verified sources across clinical registries, regulatory databases, published research, and market intelligence. The model is purpose-built for life sciences, not a general-purpose system retrofitted to the domain.

Validation is not a final step. It is built into the workflow at the point of generation. Every output is accompanied by its evidence layer. Every analysis can be interrogated. The system is designed so that when a leadership team asks “where does this come from?”, there is a clear and documented answer.

This is what it means, in practice, to bridge life sciences domain expertise with technology. Not to offer a good AI tool with a life sciences skin on it, but to engineer the insight infrastructure from first principles with the specific requirements of the sector in mind.

What Comes Next in This Series

This article is the first in a series focused on the technology side of what Omnitheia has built. In the articles that follow, Sterling and Mahesh will go deeper on specific aspects of the platform architecture: how the Evidence Builder works, how Confidence Score’s are calculated, and what it means to design an agentic AI system for an industry where hallucinations are not just an inconvenience but a genuine risk.

The life sciences sector deserves insight infrastructure purpose-built to the standards the industry demands. That is what we are building.

This is the first article in our Technology Series. Follow Omnitheia on LinkedIn for the next installments, and meet the wider team on our About Page.